Myxredlin
Insulin human biosimilar developed by Baxter. Reference product Humulin (Lilly); Actrapid, Insulatard and Mixtard (Novo Nordisk); Insuman (Sanofi).
About Myxredlin
Myxredlin is Baxter's ready-to-use human insulin in an intravenous bag for hospital use. Health Canada assessed it as a biosimilar in 2022, the only human insulin with that status in the seven markets. In the United States it was approved as a drug in 2019, and a European application under the name Inpremzia was withdrawn.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada · Myxredlin
Health CanadaApprovedIndia
Not listed by CDSCO.
United Arab Emirates
Not listed by EDE.
Same developer, other molecules
Other biosimilars in the Atlas developed by Baxter: Axberi, Inpremzia.
Chronology
- HCAug 2022Notice of Compliance, Health Canada
Sources
Planning insulin human biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant